Podcasts > Archived Podcasts > Industry Focus
This show is no longer producing new episodes. Check out our other shows.
Industry Focus
Healthcare: Is Biogen A Beat-Up Bargain? And Is Bristol-Myers' Mega-Merger On the Rocks?
Mar 27, 2019 (26:31)
Biogen's shares fell 30% because it's bailing on a once-promising Alzheimer's disease drug, but it might not be a bargain worth buying yet. Also, why a shareholder revolt could cause Bristol-Myers and Celgene's merger to fall apart.
Check out more of our content here:
- https://www.fool.com/podcasts/?utm_source=podcasts&utm_medium=podcasts&utm_campaign=industryfocus" rel="noopener" target="_blank">TMF's podcast portal
- https://www.youtube.com/user/TheMotleyFool" rel="noopener" target="_blank">YouTube
- https://twitter.com/mfindustryfocus?lang=en" rel="noopener" target="_blank">Twitter
- https://m.facebook.com/groups/217114601988296">Join Our Motley Fool Podcast Facebook Group
- https://www.linkedin.com/company/the-motley-fool">LinkedIn
- https://www.fool.com/ecap/the_motley_fool/stock-up/?aid=9205&source=isusitsz0000002&ftm_cam=stockup&ftm_veh=sidebarhelp&ftm_mes=signup"> StockUp, The Motley Fool's weekly email newsletter
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.